Osteopontin/OPN Antibody [Alexa Fluor® 532]

• Reactivity: Mu
• Applications: WB, IHC, B/N, ELISA(Cap), ELISA(Det), ICC/IF
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor 532

Osteopontin/OPN Antibody [Alexa Fluor® 532] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse Osteopontin/OPN (R&D Systems, Catalog # 441-OP)
  Leu17-Asn294 (Glu99Gly)
  Accession # Q547B5
• Specificity: Detects mouse Osteopontin (OPN) in ELISAs and Western blots.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair)
  • ELISA Detection (Matched Antibody Pair)
  • Immunocytochemistry
  • Immunohistochemistry
  • Neutralization
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 degreesC as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Osteopontin/OPN Antibody [Alexa Fluor® 532]

• BNSP
• Bone sialoprotein 1
• Eta-1
• MGC110940
• Nephropontin
• OPN
• Osteopontin
• secreted phosphoprotein 1bone sialoprotein I, early T-lymphocyteactivation 1)
• secreted phosphoprotein-1 (osteopontin, bone sialoprotein)
• Spp1
• SPP-1
• SPP1/CALPHA1 fusion
• Urinary stone protein
• uropontin

Background

Osteopontin (OPN, previously also referred to as transformation-associated secreted phosphoprotein, bone sialoprotein I, 2ar, 2B7, early T lymphocyte activation 1 protein, minopotin, calcium oxalate crystal growth inhibitor protein), is a secreted, highly acidic, calcium-binding, RGD-containing, phosphorylated glycoprotein originally isolated from bone matrix. Subsequently, OPN has been found in kidney, placenta, blood vessels and various tumor tissues. Many cell types (including macrophages, osteoclasts, activated T cells, fibroblasts, epithelial cells, vascular smooth muscle cells, and natural killer cells) can express OPN in response to activation by cytokines, growth factors or inflammatory mediators. Elevated expression of OPN has also been associated with numerous pathobiological conditions such as atherosclerotic plaques, renal tubulointerstitial fibrosis, granuloma formations in tuberculosis and silicosis, neointimal formation associated with balloon catheterization, metastasizing tumors, and cerebral ischemia. Mouse OPN cDNA encodes a 294 amino acid (aa) residue precursor protein with a 16 aa residue predicted signal peptide that is cleaved to yield a 278 aa residue mature protein with an integrin binding sequence (RGD), and N- and O-glycosylation sites. OPN has been shown to bind to different cell types through RGD-mediated interaction with the integrins alpha v beta 1 alpha v beta 3 alpha v beta 5 and non-RGD-mediated interaction with CD44 and the integrins alpha 8 beta 1 or alpha 9 beta 1 . Functionally, OPN is chemotactic for macrophages, smooth muscle cells, endothelial cells and glial cells. OPN has also been shown to inhibit nitric oxide production and cytotoxicity by activated macrophages. Human, mouse, rat, pig and bovine OPN share from approximately 40-80% amino acid sequence identity. Osteopontin is a substrate for proteolytic cleavage by thrombin, enterokinase, MMP-3 and MMP-7. The functions of OPN in a variety of cell types were shown to be modified as a result of proteolytic cleavage (2, 3).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q547B5()